|Search by 》Keyword or Keyphrase 〉Luxturna|
LUXTURNA® (voretigene neparvovec-rzyl)
: is a prescription gene therapy product used for the treatment of patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can only be confirmed through genetic testing.
: is a novel gene therapy for the treatment of Leber’s congenital amaurosis. It was developed by Spark Therapeutics and Children’s Hospital of Philadelphia. It is the first in vivo gene therapy approved by the FDA.
Other names: voretigene neparvovec-rzyl
License data: US DailyMed: Voretigene-neparvovec; US FDA: Luxturna